… This inhibition can be overcome by mutating either the exon’s 5 or 3 splice site to make it
correspond more closely to the relevant consensus sequence. Two separate sequence …

… an activating epidermal growth factor receptor (EGFR) … They received either erlotinib or
gefitinib once a day. Out of … tumors during their disease course, either whole brain radiotherapy or …

… growth factor (VEGF) is an apparently endothelial cell-specific mitogen that is structurally
related to platelet-derived growth factor… gene is split among eight exons and that the various …

… A total of 375 patients with recurrent or metastatic stage IIIB/IV NSCLC, who had either exon
19 deletion or the L858R mutation in exon 21, and had received either gefitinib (n = 228) or …

… Seventy patients (24%) were found to have either EGFR exon 19 deletion or EGFR
L858R. The clinical characteristics of patients tested for EGFR mutations are listed in Table 1. …

… The primary focus of this analysis is patients with either exon 19 deletions or L858R point
mutations. Table 1 shows the baseline characteristics of the patients found to have one of …

… IIIb and IIIc were transfected into DT3 and AT3 cells, we observed a predominant product
that consisted of either exon IIIb or exon IIIc spliced between the adenovirus upstream (U) …

… To evaluate clinical differences between the two most common EGFR mutations, we
retrospectively analysed RR and survival of advanced NSCLC patients harbouring either the exon …

… in a 2:1 ratio to receive either 150 mg of erlotinib daily or a … 90% of these mutations occur at
exons 19 and 21 near the ATP … The most common mutations in the EGFR gene are an exon …

… growth factor receptor 2 exon IIIc. In cells that normally include this exon, we show that the
overexpression of either hnRNP H1 or hnRNP F resulted in the dramatic silencing of exon IIIc. …